E2F4 biomarker can help predict prognosis and response to BCG therapy in bladder canc
Investigators from Dartmouth's Norris Cotton Cancer Center harnessed genomic data to discover that the previously identified E2F4 signature in breast cancer can be utilized to predict prognosis and response to therapy in bladder cancer.